Skeletal Disease in Primary Hyperparathyroidism
Session approved for 1 ASRT Category A Credit
Session approved for up to 1 AMA PRA Category 1 Credits™
This session duration is 50 minutes.
Primary hyperparathyroidism is a common endocrine disorder and a common secondary cause of osteoporosis. Patients with mild, asymptomatic disease may have reductions in both cortical and trabecular bone. Fracture risk is elevated, particularly risk for vertebral fractures. In this session, we will explore bone loss in primary hyperparathyroidism and discuss medical and surgical management of the disease.
- Describe the bone loss that occurs in patients with primary hyperparathyroidism.
- Identify patients with primary hyperparathyroidism who meet guideline recommendations for parathyroid surgery.
- Develop a medical management plan for patients with primary hyperparathyroidism and bone disease.
Natalie Cusano, MD, MS, CCD
Director, Bone Metabolism Program
Lenox Hill/Northwell Health
Dr. Natalie Cusano is an Associate Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell and Director of the Bone Metabolism Program in the Division of Endocrinology at Lenox Hill Hospital in New York. She received her undergraduate training at the Massachusetts Institute of Technology and her medical training at the Boston University School of Medicine. She completed residency training in Internal Medicine at Beth Israel Deaconess Medical Center and fellowship training in Endocrinology, Diabetes & Metabolism at the College of Physicians & Surgeons, Columbia University. She serves as a member of the Endocrine Society Endocrine Board Review Faculty Group. She serves on the editorial board of Endocrine Practice. She lists over 100 publications of original research, invited articles, chapters and abstracts in the field of metabolic bone disease.
Alexion (Self) : Speaker's Bureau / Teaching Engagements (Status: Ongoing); Ascendis (Self) : Data Safety Monitoring Board (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); Shire/Takeda (Self) : Research Support (Status: Ongoing)
Rachel Pessah-Pollack, FACE (Moderator)
Clinical Associate Professor
NYU Langone Hospitals
Rachel Pessah-Pollack, M.D., F.A.C.E. is a Clinical Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at NYU Langone Health in New York City. She trained at the Mount Sinai School of Medicine in New York City, where she completed her Internal Medicine Residency and Endocrinology Fellowship and is Board Certified in Endocrinology, Diabetes & Metabolism. She was elected in 2019 to the American Association of Clinical Endocrinologists (AACE) Board of Directors for a three-year term. She has served as Chair of the AACE Clinical Practice Guidelines Oversight Committee and Chair of the AACE Women's Leadership Dinner in 2019. She served as Chair of the American College of Cardiology's (ACC) Diabetes Collaborative Registry Stakeholder Advisory Committee from 2018-2019. She has been named a New York Times Super Doctor (2017-2019) and New York Times Super Doctor Rising Star (2014-2016.) She is a frequent contributor to Health Monitor publications for patients and is on the Advisory Board of Endocrine Today. She is a coauthor of numerous peer-reviewed articles and clinical practice guidelines including the recently published AACE Postmenopausal Osteoporosis Guidelines. Dr. Pessah-Pollack specializes in metabolic bone disease and lectures nationally on the topic of postmenopausal osteoporosis. She remains actively involved in medical education and the training of endocrine fellows.
Boehringer Ingelheim/Eli Lilly (Self) : Advisory Board (Status: Ongoing); Health Monitor (Self) : Advisory Board (Status: Ongoing); Radius (Self) : Advisory Board (Status: Terminated --- 6/2020); Sanofi (Self) : Advisory Board (Status: Terminated --- 6/2020)